The company is the world's largest manufacturer and supplier of PPR vaccines, having ~75% of the world market. While operating across four broad verticals of Poultry Vaccines, Poultry Health Products, Animal Vaccines and Animal Health Products, the company provides services like seroprofiling kits and diagnostic labs for poultry flocks, and mastitis control programs for cattle. The company owns and operates Asia's largest single-location animal biological manufacturing facility.
Cyborg Score Rationale
Hester holds exceptional global market positions in niche vaccine segments, but recent financial performance has deteriorated sharply. Hester Biosciences' consolidated net profit fell 73.94% to Rs 1.29 crore in Q4 FY25, despite a 3.37% increase in net sales to Rs 81.93 crore. The company faces headwinds from profitability challenges despite strong revenue base.
Top Insights
World's largest PPR vaccine manufacturer with ~75% global market share; 70%+ market share in Goat Pox vaccine in India
Q4 FY25 net profit collapsed 73.94% YoY to Rs 1.29 crore, signaling severe operational stress despite flat revenue growth
Recent CFO change with Ashish Desai (25-year CA with finance expertise) appointed November 2025, suggesting management restructuring
Strategic partnerships with Bill & Melinda Gates Foundation and GALVmed provide credibility for development programs
Named Competitors
Poultry Vaccines (India Market) — Other Indian poultry vaccine manufacturers capturing remaining market share
Animal Healthcare Products — Global competitors in veterinary vaccine and diagnostics space
Recent Developments
(January 2026) Board meeting held to discuss quarterly results